In September 1976, a Belgian microbiologist named Peter Piot received a thermos in the mail. Inside, packed in melting ice, sat two vials of blood drawn from a nun dying of a mysterious hemorrhagic fever in Yambuku, a remote village in what was then Zaire. When Piot and his colleagues at the Institute of Tropical Medicine in Antwerp examined the sample under an electron microscope, they saw something no scientist had documented before: a long, threadlike virus shaped like a shepherd’s crook. They named it after the Ebola River, which flowed near the village where the first cases appeared.
That 1976 outbreak killed 280 of the 318 people it infected, an 88% case fatality rate. Nearly 50 years later, the virus is back in the same country. On May 17, 2026, the World Health Organization declared a new Ebola outbreak a public health emergency of international concern. The strain this time is Bundibugyo, one of five Ebola species that cause disease in humans, and it carries a critical vulnerability: no approved vaccine or treatment exists for it.
In This Article
- What the Ebola virus does inside the human body
- How it spreads (and the persistent myth about airborne transmission)
- The five species and why the strain matters
- A timeline of outbreaks from 1976 to 2026
- Why Bundibugyo is forcing the global health community to start over
What the virus does to a human body
Ebola is a filovirus, named for its filament shape. Under a microscope, the particles look like tangled threads or tiny worms, a structure unlike almost any other human pathogen.
Once the virus enters through broken skin, mucous membranes, or contact with infected bodily fluids, it targets a specific class of immune cells: dendritic cells and macrophages. These are the very sentinels your immune system relies on to detect invaders. This is what makes Ebola especially dangerous. It does not simply evade the immune response; it hijacks it.
Infected immune cells carry the virus to lymph nodes, the liver, and the spleen, spreading it throughout the body while simultaneously disabling the alarm system that should be rallying a defense. The virus replicates explosively inside these cells, releasing new viral particles that infect surrounding tissue.
As the infection progresses, the virus attacks the endothelial cells lining blood vessels. These cells normally keep blood where it belongs. When Ebola damages them, vessels become leaky. Fluid seeps into surrounding tissue. Clotting factors are consumed faster than the body can replace them, a condition called disseminated intravascular coagulation. The result is a paradox: the patient bleeds internally while blood clots form in small vessels throughout the body, starving organs of oxygen.
The clinical progression follows two phases. The “dry” phase begins 2 to 21 days after exposure and resembles many other infections: fever, headache, muscle pain, fatigue. The “wet” phase brings vomiting, diarrhea, and in severe cases, hemorrhaging from the eyes, gums, and internal organs. Death, when it occurs, typically results from multi-organ failure and shock.
How it spreads (and why it is not airborne)
One of the most persistent misconceptions about Ebola is that it travels through the air. It does not. Unlike influenza or COVID-19, Ebola requires direct contact with the bodily fluids of an infected person: blood, vomit, feces, saliva, sweat, breast milk, or semen. Contaminated surfaces (bedding, medical equipment, needles) are also transmission routes.
This makes the virus simultaneously easier and harder to contain than respiratory pathogens. Easier, because isolation and protective equipment can break the chain. Harder, because the virus spreads through the exact actions that caregivers, healthcare workers, and family members perform instinctively: holding a sick child, washing a dying relative, preparing a body for burial. In much of Central and West Africa, traditional funeral practices involve close physical contact with the deceased, and these rituals have been primary drivers of every major outbreak.
Healthcare workers face elevated risk. In the current 2026 outbreak, the CDC reports that the index case was itself a health worker who developed symptoms on April 24, 2026. Proper personal protective equipment reduces risk dramatically, but in resource-limited settings, PPE shortages remain a persistent problem.
A key detail that affects containment strategy: a person with Ebola is not contagious during the incubation period (before symptoms appear). Infectiousness begins at symptom onset and persists as long as the virus remains in the blood. In survivors, the virus can linger in semen for months after recovery.
Five species, and the strain determines everything
Six species of Orthoebolavirus have been identified. Five cause disease in humans, though their severity and the tools available to fight them differ enormously.
Ebola virus (Zaire ebolavirus) is the most lethal, responsible for both the original 1976 Yambuku outbreak and the catastrophic 2013-2016 West Africa epidemic. Case fatality rates have ranged from 25% to 90%. Two approved vaccines (Ervebo and Zabdeno/Mvabea) and two monoclonal antibody treatments (mAb114 and REGN-EB3) target this species specifically.
Sudan virus is the second most common species, responsible for outbreaks including a 2022 event in Uganda. Fatality rates range from 40% to 60%. No approved vaccine or treatment exists, though a candidate vaccine reached Phase 2 trials in 2023.
Bundibugyo virus, first identified in Uganda’s Bundibugyo district in 2007, carries fatality rates between 25% and 50%. No approved vaccine or treatment exists. This is the species driving the 2026 outbreak.
Taï Forest virus, identified in 1994 in Côte d’Ivoire, has produced only one known human case (a researcher who survived).
Reston virus, discovered in monkeys imported to Reston, Virginia in 1989, can infect humans but has never caused symptomatic disease.
The species distinction matters because vaccines and treatments are not interchangeable. Ervebo, deployed with extraordinary effectiveness during the 2018-2020 DRC outbreak, protects only against Zaire ebolavirus. The WHO states it is not expected to protect against Bundibugyo or other species. When a different species causes an outbreak, the medical arsenal effectively resets to zero.
From Yambuku to Ituri: 50 years of outbreaks
1976, Zaire and Sudan. Two simultaneous outbreaks in Central Africa introduced the world to Ebola. The Zaire outbreak killed 280 of 318 infected. The Sudan outbreak killed 151 of 284. Scientists identified the virus, named it, and then watched it seemingly vanish.
1995, Kikwit, DRC. A Zaire ebolavirus outbreak killed 254 people, confirming that the virus had not disappeared. It had simply retreated into its animal reservoir: fruit bats of the Pteropodidae family, the suspected natural host.
2007, Bundibugyo, Uganda. The Bundibugyo species was identified for the first time, infecting 149 people and killing 37 (a 25% fatality rate). The strain proved genetically distinct enough to be classified as a separate species.
2013-2016, West Africa. The largest Ebola epidemic in history. Zaire ebolavirus spread across Guinea, Liberia, and Sierra Leone, infecting more than 28,600 people and killing 11,325. The WHO declared it a public health emergency of international concern in August 2014. The crisis galvanized vaccine development, and Ervebo received FDA approval in 2019.
2018-2020, DRC. A Zaire ebolavirus outbreak in North Kivu and Ituri provinces infected 3,481 people and killed 2,299. Ervebo was deployed for the first time in an active outbreak, demonstrating 97.5% efficacy and helping contain the spread.
2026, DRC and Uganda. The current Bundibugyo virus outbreak. The index case, a health worker, developed symptoms on April 24. WHO was not alerted until May 5, creating a gap of nearly two weeks during which the virus spread unchecked across multiple health zones. As of May 19, 2026, the CDC reports 536 suspected cases, 105 probable cases, 34 confirmed cases, and 134 deaths across nine health zones in Ituri Province, DRC. Uganda has confirmed two imported cases, including one death. An American healthcare worker tested positive on May 17 and was transferred to Germany for treatment.
Why Bundibugyo forces a reset
The 2026 outbreak confronts the global health community with a problem it has not faced since before Ervebo’s approval: a major Ebola outbreak with no vaccine.
During the 2018-2020 DRC outbreak, ring vaccination (vaccinating contacts of confirmed cases and contacts of those contacts) proved remarkably effective. That tool is not available for Bundibugyo. Candidate vaccines based on vesicular stomatitis virus platforms have shown promise in nonhuman primate studies, but none have entered late-stage human trials. The monoclonal antibody therapies approved for Zaire ebolavirus have not been tested against Bundibugyo and are not expected to work, as the surface proteins the antibodies target differ between species.
Treatment is limited to supportive care: intravenous fluids, electrolyte management, oxygen therapy, and management of secondary infections.
The context compounds the challenge. Ituri Province has experienced armed conflict for decades. Healthcare infrastructure is sparse. The gap between the first symptoms and WHO notification gave the virus time to establish transmission chains across multiple health zones before containment efforts began.
The United States has responded with enhanced airport screening for travelers from DRC, Uganda, and South Sudan, along with entry restrictions for non-US passport holders who recently visited affected areas. Domestically, 46 Laboratory Response Network facilities can test for the virus, and 13 Regional Emerging Special Pathogen Treatment Centers are prepared to handle confirmed cases. The CDC assesses the risk of domestic spread as low: Ebola’s transmission requirements (direct fluid contact) make it far less contagious than respiratory viruses, and every prior case imported to the US or Europe has been contained without community spread.
But the critical question is containment at the source. The 2013-2016 West Africa epidemic proved Ebola can overwhelm health systems when the response arrives late. The 2018-2020 DRC outbreak proved vaccines can tip the balance. The 2026 Bundibugyo outbreak is testing what happens when the delay is long and the vaccine does not yet exist.